Basic Information


GTO ID GTC0604
Trial ID ChiCTR1900023957
Disease Acute Lymphoblastic Leukemia
TherapyCAR-T cell
Treatment CAR-T cells
Co-treatment HSCT
Recruitment statusRecruiting
TitleCAR-T therapy followed by haploidentical HSCT have prominent therapeutic efficacy for patients with relapsed/refractory acute lymphoblastic leukemia
Year2019
CountryChina
Company sponsorthe First Affiliated Hospital, School of Medicine, Zhejiang University

Clinical Result

Cohort1: HSCT
Administration route None
Dosage 5E6 cells/kg
Donor type Autologous|Allogeneic
Pts 55
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 100%(CR); 2-year overall survival:77.0%
Adverse reactions 13/67(Grade ≥3 CRS)
References PMID: 32366260
Cohort2: no HSCT
Administration route None
Dosage 3E6 cells/kg
Donor type Autologous|Allogeneic
Pts 67
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 100%(CR); 2-year overall survival:36.4%
Adverse reactions 32/67(Grade ≥3 CRS)
References PMID: 32366260

Relationship Graph

Overview of Knowledge Graph